Important Safety Information
This site is intended for US healthcare professionals only. U.S. healthcare professionals only. Visit patient site

FreeStyle Libre 14 day system

The first and only 14 day personal glucose monitoring (CGM) solution clinically proven
to reduce time spent in hypoglycemia.2,3


Now featuring 14 day wear with a fast,
1-hour warm-up time


The only CGM to maintain accuracy1 over 14 days without the need for fingerstick calibration or sensor coding


Most commercially insured patients will pay between $40 and $75 per month*

See FreeStyle Libre Pro

FreeStyle Libre Pro:
Professional continuous glucose monitoring (CGM) made easy

Reader stays in office
No fingerstick calibration for patients
Up to 14 days of glucose readings and patterns
Reimbursable procedure with broad coverage

See FreeStyle Libre 14 day

Learn more about the new
FreeStyle Libre 14 day personal CGM system

FreeStyle Libre 14 day System Coverage Information

FreeStyle Libre 14 day system is more affordable personal CGM for your patients*

Homepage Panel

Have a sales representative tell you more

A rep can keep you informed about new and existing Abbott products

* Based on the manufacturers' list prices. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

† Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.

‡ Coverage is limited to patients for whom professional CGM is medically necessary. Individual plan coverage may vary. Always verify coverage criteria and frequency directly with the payer.

Reference: 1. FreeStyle Libre 14 day User's Manual. 2. Bolinder, Jan, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. The Lancet 388.10057 (2016): 2254-2263. 3. Haak, Thomas, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Therapy 8.1 (2017): 55-73.

ADC-05526 Ver 10.0 11/18


Disclaimer is a product-specific website intended only for residents of the United States.

If you are a resident of another country, please visit our global directory to locate the appropriate site for your country.

You are about to leave for a 3rd party website

The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.

Do you wish to leave this site?

Thank you for submitting your details. We will contact you as soon as possible.